Endothelin as a therapeutic target the treatment of cardiovascular disease

Heart Disease

Volumn 3, Issue 3, 2001, Pages 176-188

  Kaur, S ^a   Frishman, W H ^a   Singh, I ^a   Tamirisa, P ^a   Kumar, A ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Cardiovascular conditions; Endothelin; Endothelin antagonists; Endothelin receptors

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST;

ACUTE KIDNEY FAILURE; ASTHMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DRUG STRUCTURE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; MITOGENESIS; NEPHROTOXICITY; PARACRINE SIGNALING; PULMONARY HYPERTENSION; REVIEW; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

EID: 0035209608     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00132580-200105000-00008     Document Type: Review

References (188)

1. Characterisation of a coronary vasoconstrictor produced by cultured endothelial cells
2. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
3. Sarafotoxin, a novel vasoconstrictor peptide: Phosphoinositide hydrolysis in rat heart and brain
4. Endothelins: Myocardial actions of a new class of cytokines
5. The human preproendothelin-1 gene
6. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
7. Molecular biology and biochemistry of the endothelins
8. Clinical experience with endothelin antagonists
9. The endothelin system and its potential as a therapeutic target in cardiovascular disease
10. Increased plasma concentration of endothelin-1 and big endothelin-1 in acute myocardial infarction
11. What turns on the endothelins?
12. Structure of mouse preproendothelin-3 and phylogenetic analysis of the endothelins
13. Cloning and functional expression of human endothelin converting enzyme CDNA
14. Endothelin: New discoveries and rapid progress in the clinic
15. Functional significance of the isoforms of endothelin-converting enzyme-1
16. Inactivation of endothelin 1 by an enzyme of the vascular endothelial cells
17. Endothelins are more sensitive than sarafotoxins to neutral endoproteinase: Possible physiological significance
18. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase)
19. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelin derived relaxing factor
20. Tissue distribution and half-life of 125I-endothelin in the rats: Importance of pulmonary clearance
21. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044
22. Mechanisms of disease: Endothelin
23. Molecular pharmacology of endothelin converting enzymes
24. Cloning and expression of a cDNA encoding an endothelial receptor
25. Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor
26. Molecular characterisation of the endothelin receptors
27. Cloning and functional expression of human cDNA for the ETB endothelin receptor
28. The current endothelin receptor classification: Time for reconsideration?
29. Endothelins: Vascular actions and clinical implications
30. Cloning and expression of human endothelin-1 receptor cDNA
31. Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells
32. Cytokines in context
33. Endothelin and calcium signaling in NG 108-15 neuroblastoma X glioma cells
34. Mobilization of intracellular calcium by ET in Swiss 3T3 cells
35. A novel vasoactive peptide stimulates mitogenesis through inositol lipid turnover in Swiss 3T3 fibroblasts
36. The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae
37. Endothelins: From receptors to medicine
38. Endothelin-mediated stimulation of DNA synthesis in vascular smooth muscle cells
39. The calcium antagonist nifedipine inhibits arterial smooth muscle proliferation
40. Growth regulatory properties of endothelins
41. Endothelin stimulates DNA synthesis in Swiss 3T3 cells, synergy with polypeptide growth factors
42. Effects of pH on the myofilaments and the sarcoplasmic reticulum of skinned cells from cardiac and skeletal muscles
43. The effects of changes of pH on intracellular calcium transits in mammalian cardiac muscle
44. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells
45. Endothelin stimulates phospholipase C, Na+/H+ exchange, c-fos expression, and mitogenesis in rat mesangial cells
46. Endothelin: A new vasoactive ocular peptide
47. ET-1 and ET-3 induce vasorelaxation via common generation of endothelium derived nitric oxide
48. Cloning and sequence analysis of cDNA encoding human non-selective type of endothelin receptor
49. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats
50. Modulators of calcium and potassium channels: Their effects on endothelin-1 binding to cardiac membranes
51. The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in anaesthetised dogs
52. Suppression of ventricular arrhythmias after coronary artery ligation by pinacidil, a vasodilator drug
53. Endothelin antagonists
54. Contribution of endogenous generation of endothelin-1 to basal vascular tone
55. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans
56. Pulmonary big endothelin affects coronary tone and leads to enhanced, ET(A)-mediated coronary constriction in early endothelial dysfunction
57. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy
58. Endothelin antagonists in salt-dependent hypertension associated with renal insufficiency
59. Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: Correlation with vascular structure
60. Endothelin and endothelin antagonists in hypertension
61. Plasma immunoreactive endothelin-1 in experimental malignant hypertension
62. Hypertension associated with endothelin-secreting malignant hemangioendothelioma
63. Plasma endothelin in human essential hypertension
64. Effects of endothelin on the renal artery from spontaneously hypertensive and Wistar Kyoto rats
65. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension
66. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension
67. Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents
68. Angiotensin II stimulates endothelin-1 release from human endothelial cells
69. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury
70. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: Reversal by ET(A)-receptor antagonist
71. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition
72. Bosentan Hypertension Investigators. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
73. Age and sex-related variation of plasma endothelin-1 concentration in normal and hypertensive subjects
74. Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in males
75. Vascular endothelin responsiveness and receptor characteristics in vitro and effects of endothelin receptor blockade in vivo in cyclosporin hypertension
76. Bosentan ameliorates cyclosporin A-induced hypertension in rats and primates
77. Plasma endothelin-1 and big endothelin-1 levels in women with pre- eclampsia
78. Potential role of endothelin-1 in normal and hypertensive pregnancies
79. Endothelin-1 stimulates the proliferation and invasion of first trimester trophoblastic cells in vitro: A possible role in the etiology of pre-eclampsia?
80. Endothelin in chronic renal failure
81. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients
82. Elevated immunoreactive endothelin levels in patients with pheochromocytoma
83. Oxidized low density lipoprotein induces mRNA expression and release of ET from human and porcine endothelium
84. Modified low-density lipoproteins activates macrophages to secrete ir-ET
85. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis
86. Up-regulation of endothelin B receptors in atherosclerotic human coronary arteries
87. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans
88. The endothelin family: Local hormones with diverse roles in health and disease?
89. Vascular responses to endothelin-1 in atherosclerotic primates
90. Modulation of endothelin-1 coronary vasoconstriction in spontaneously hypertensive rats by the nitric oxide system
91. Insulin stimulates endothelin binding and action on cultured vascular smooth muscle cells
92. Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis
93. A potential role for endothelin-1 in peripheral vascular disease
94. Effects of endothelin on coronary flow, mechanical performance, oxygen uptake and formation of purines and on outflow of prostacyclin in the isolated rabbit heart
95. Dose-dependent effect of endothelin-1 on blood flow to normal and collateral-dependent myocardium
96. Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor
97. Endothelins: A potent vasoconstrictor associated with coronary vasospasm
98. Proarrhythmic activity of intracoronary endothelin in dogs: Relation to the site of administration and to changes in regional flow
99. Contribution of endogenous endothelins to the extension of myocardial infarct size in rats
100. Plasma endothelin determination as a prognostic indicator of 1 year mortality after acute myocardial infarction
101. Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function
102. Endothelin release during ischemia and reperfusion of isolated perfused rat hearts
103. Endothelin-1 in patients with complicated and uncomplicated myocardial infarction
104. Plasma immunoreactive endothelin in the acute and subacute phases of myocardial infarction in patients undergoing fibrinolysis
105. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure
106. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion
107. Effects of an endothelin receptor antagonist TAK-044 on myocardial energy, metabolism in ischemia/reperfused rat hearts
108. Role of endogenous endothelin in chronic heart failure: Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling
109. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: Possible involvement of myocardial endothelin system in ventricular remodeling
110. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat
111. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease
112. Endothelin-1 receptors in cultured vascular smooth muscle cells and cardiocytes of rats
113. Effects of endothelin-1 on left ventricular performance in conscious dogs: Assessment by pressure-volume analysis
114. A receptor antagonist
115. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: Blockade with SB 209670
116. Endothelin in heart failure: Temporal evolution, source of production and interaction with atrial natriuretic peptide
117. Role of endothelin receptor subtypes in volume-stimulated ANF secretion
118. Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins
119. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure
120. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function
121. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure
122. Increased plasma concentrations of endothelin in congestive heart failure in humans
123. Plasma big-endothelin levels, cardiac autonomic neuropathy, and cardiac functions in patients with insulin-dependent diabetes mellitus
124. Infection of cultured human endothelial cells increases endothelin levels
125. Contribution of endothelin-1 to myocardial injury in a murine model of myocarditis. Acute effects of bosentan, and endothelin receptor antagonist
126. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Endothelin antagonism in heart failure
127. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
128. Endothelin as a regulator of cardiovascular function in health and disease
129. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors
130. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
131. Effects of combined endothelin A receptor blockade plus ACE inhibition in rats with chronic heart failure
132. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure
133. Selective or non-selective endothelin receptor blockade in chronic heart failure?
134. Changes in plasma endothelin-1 levels reflect clinical response to beta blockade in chronic heart failure
135. Endothelin-1: Mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells
136. ET-1 induces hypertrophy with enhanced expression of muscle specific genes in cultured neonatal rat cardiomyocytes
137. Endothelins and cardiac hypertrophy
138. Endothelins are angiogenic
139. Endothelin stimulates protein synthesis in smooth muscle cells
140. Prolonged endothelin blockade prevents hypertension and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats
141. Possible involvement of endothelin-1 in cardiac hypertrophy
142. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes
143. Mild hypoxia induces hypertrophy of cultured neonatal rat cardiomyocytes: A possible endogenous endothelin-1-mediated mechanism
144. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload
145. Respective role of humoral factors and blood pressure in cardiac remodeling of DOCA hypertensive rats
146. A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty: Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670
147. Orally active endothelin receptor antagonist BMS-182874 suppresses neointimal development in balloon-injured rat carotid arteries
148. Role of endogenous endothelin in the development of graft arteriosclerosis in rat cardiac allografts: Antiproliferative effects of bosentan, a nonselective endothelin receptor antagonist
149. Endothelin A receptor antagonism may prevent in-stent restenosis in humans
150. The selective endothelin-A-receptor antagonist LU 135.252 inhibits the direct arrhythmogenic action of endothelin-1
151. Bosentan the mixed endothelin-A- and B-receptor antagonist suppresses intrapericardial endothelin-1-induced ventricular arrhythmias
152. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?
153. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
154. Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia
155. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension
156. Role of vasoactive mediators in primary and secondary pulmonary hypertension
157. Fenfluramine potentiates canine pulmonary vasoreactivity to endothelin- 1
158. Post-cardiopulmonary bypass pulmonary hypertension in lambs with increased pulmonary blood flow. A role for endothelin 1
159. Plasma endothelin-1 levels in Takayasu's arteritis
160. Endothelin-1- and endothelin-receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease
161. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats
162. Effects of the endothelin ET(A) receptor antagonist, TA-0201, on pulmonary arteries isolated from hypoxic rats
163. The effect of the ETA receptor antagonist (CI-1020) in rats with established hypoxic pulmonary hypertension
164. The combined treatment of oral endothelin (ET)-A receptor antagonist and oral prostacyclin (PGI2) analog is more greatly effective in ameliorating pulmonary hypertension (PH) and right ventricular (RV) hypertrophy than each drug alone in rats
165. Endothelin A receptor antagonism improves pulmonary and systemic hemodynamics in patients with severe pulmonary hypertension
166. Epithelially-derived endothelin and nitric oxide in asthma
167. Immunoreactive endothelin in bronchial biopsy specimens: Increased expression in asthma and modulation by corticosteroid therapy
168. Effects of dexamethasone on the basal and cytokine-stimulated release of endothelin-1 from guinea-pig cultured tracheal epithelial cells
169. Endothelin receptor antagonists inhibit antigen-induced lung inflammation in mice
170. Increased synthesis and release of endothelin-1 during the initial phase of airway inflammation
171. Distribution of immunoreactive endothelin in the lungs of mice during respiratory viral infection
172. Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1
173. Cranial and cardiac neural crest detects in endothelin-A receptor- deficient mice
174. Targeted and natural (piebaldlethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice
175. A missense mutation of the endothelin B receptor gene in multigenic Hirschsprung's disease
176. Regulation of the cerebral circulation: Role of endothelium and potassium channels
177. Blockade and reversal of endothelin-induced constriction in pial arteries from human brain
178. Increased endothelin concentration in CSF from patients with subarachnoid hemorrhage
179. Prevention of cerebral vasospasm by a novel endothelin receptor antagonist, TA-0201
180. Nonpeptide endothelin antagonist. Cerebrovascular characterization and effects on delayed cerebral vasospasm
181. A novel endothelin antagonist, A-127722, attenuates ischemic lesion size in rats with temporary middle cerebral artery occlusion: A diffusion and perfusion MRI study
182. Nonpeptide endothelin receptor antagonists. III. Effect of SB 209670 and BQ123 on acute renal failure in anesthetized dogs
183. BQ-123, a specific endothelin (ETA) receptor antagonist, prevents ischemia-reperfusion injury in kidney transplantation
184. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes
185. Localization of sites of enhanced expression of endothelin-1 in the kidney of DOCA-salt hypertensive rats
186. Renal and vascular effects of chronic endothelin receptor antagonism in malignant hypertensive rats
187. Radiocontrast media induced endothelin-1 mRNA expression and peptide release in porcine aortic endothelial cells
188. Targeted disruption of the endothelin-B-receptor gene attenuates inflammatory nociception and cutaneous inflammation in mice